Nostos Genomics builds AI-driven software to accelerate rare disease diagnostics by automating variant interpretation for genetic testing laboratories. Their mission is to reduce the interpretation bottleneck in genomics so labs can deliver faster, more accurate diagnoses at scale. The company is GDPR-compliant and their platform is CE‑IVDR certified.

AION, the company’s core product, automatically identifies likely pathogenic variants and generates comprehensive reports and exports, enabling routine exome interpretation in under 30 minutes. AION is designed as a white-box decision support tool so human experts can verify predictions, and validation studies (2022–2025) report high sensitivity in trio analyses.

AION requires no complex implementation, supports labs in prioritizing complex cases, and aims to help genetic testing providers scale operations. Nostos Genomics regularly publishes resources such as webinars and white papers and has announced a collaboration with Limbus to advance its offerings.